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ABSTRACT
Atherosclerosis is a cardiovascular disease that is characterized by the hardening of
arteries through the formation of cholesterol plaques. Cyclodextrins could potentially treat
atherosclerosis by shrinking plaques. These cyclic oligosaccharides can make complexes
with cholesterol but have also shown toxic side effects. This study looked for potential
negative effects of cyclodextrins and cholesterol on gut bacteria. It was hypothesized that
Bacteroides vulgatus will have decreased growth when grown in broth with cholesterol. In
contrast, Clostridium bolteae will have decreased growth when grown in broth with
cyclodextrins. Due to the fact that these bacteria are anaerobic, Clostridium bolteae and
Bacteroides vulgatus, were grown using GAM broth under CO2. Data was collected by
using a spectrophotometer to measure changes in bacterial growth throughout the growth
cycle. Each bacteria was treated with one of three chemicals at one of three concentration
to make a total of 9 different conditions. α-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin,
and cholesterol with concentrations of 1 mM, 10 mM, and 100 mM. The slopes of the log
phase of bacterial growth were compared using a two tailed T-Test with α=0.05. Growth
of Clostridium bolteae was significantly inhibited for most of the cyclodextrin trials and
all the cholesterol concentrations. Bacteroides vulgatus growth was inhibited by 100 mM
concentrations of cholesterol and α-cyclodextrins. Interestingly, Bacteroides vulgatus
growth was significantly increased when grown with 1 mM and 10 mM concentrations of
cholesterol. Continued research is needed to determine when cholesterol concentrations
become harmful to Bacteroides vulgatus. Clostridium bolteae needs further research to
understand the 10 mM α-cyclodextrin trial that did not show significant inhibition. The
results demonstrate that cyclodextrins are associated with inhibited growth for these two
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gut bacteria but expansion of this test to other gut bacteria is key for a deeper understanding
of the impact that cyclodextrins would have on the gut microbiome as a whole.
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INTRODUCTION
Atherosclerosis is a cardiovascular disease that has one of the highest mortality
rates in the world. It is characterized by the formation of cholesterol-filled plaques that
are chronically inflamed and continue to develop until they occlude the artery or break
off causing a stroke or heart attack. Statins are the current standard treatment for
atherosclerosis and for the precursor to atherosclerosis, high cholesterol. These drugs
lower the levels of unhealthy lipoproteins to slow the progression of plaques (Lusis
2000). However, there remains a gap in medical treatment for a way to reduce
inflammation and remove cholesterol from plaques to lower the risk for heart attacks and
strokes. Cyclodextrins are oligosaccharides that have been found to regress
atherosclerosis by decreasing inflammation and shrinking plaques (Zimmer et al. 2016).
Cyclodextrins are known to extract cholesterol from membranes. The possible
mechanism for this removal was shown using a computer simulation; it demonstrated that
cyclodextrins form dimers to pull out cholesterol molecules, forming 2:1 cyclodextrincholesterol complexes (LóPez et al. 2011). Cholesterol is key to the structural integrity of
cell membranes; it is possible that cyclodextrins are causing changes in cell membranes
of gut bacteria that is impacting their growth. The present study was designed to test the
impact of cyclodextrins on the growth of gut bacteria.
2-Hydroxypropyl-β-cyclodextrin (HPβCD) has been shown to solubilize
cholesterol and have minimal cytotoxic effects on human cells (Szente et al. 2018).
HPβCD is being studied in clinical trials for the treatment of Niemann-Pick C, a fatal
hereditary disease that can be characterized by the buildup of cholesterol in lysosomes
(Singhal et al. 2018). HPβCD promotes the removal of cholesterol from these lysosomes
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through a similar mechanism to atherosclerotic plaque regression. HPβCD is a
frontrunner in atherosclerosis research because of its success in Niemann-Pick C clinical
trials (Singhal et al. 2018). Another commonly studied cyclodextrin for atherosclerosis
treatment is α-cyclodextrin (αCD). αCD was found to inhibit inflammatory pathways
better than HPβCD (Pilely et al. 2019). In one study, αCD was also found to decrease
obesity by improving lipid metabolism in mice. Interestingly, these mice were fed high
fat diets which negatively affected their gut microbiome; then other mice were fed the
same diet with αCD and had another large change in bacterial composition as shown in
the graph below. There was a decrease in the Bacteroides genus in mice fed a high fat
diet (HFD) but they rebounded in mice that were treated with αCD along with their HFD.
On the other hand, Clostridium cluster XIVa was increased in mice that were fed a HFD
but drastically decreased when αCD was added.

Figure 1. This graph depicts the change in gut bacteria population in mice. The three columns compare
mice fed a normal diet (ND), mice fed a high fat diet (HFD) and mice fed a HFD and treated with αCD
(Nihei et al. 2018).

These results raise the following questions: what exactly is impacting the growth
of these bacteria? Is it the high cholesterol levels, introduction of cyclodextrin or both?
Cyclodextrins are not absorbed so they must be fermented by the gut bacteria. This
means there is direct contact between the bacteria and these molecules (Amar et al.
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2016). A study done of human erythrocytes and a Caco-2 cell line showed that αCD was
cytotoxic to these cells; however, once a complex was formed with cholesterol the
cytotoxicity of αCD decreased. This same study proposed that αCD could also form
complexes with phospholipids (Roka et al. 2015). The mechanism for cyclodextrin
cytotoxicity has not been confirmed but is speculated to be related to the removal of
cholesterol from membranes and potentially removal of phospholipids as well, which
could be dangerous for the bacteria of the human microbiome. This goal of the
experiment is to observe any major cytotoxic effects that cyclodextrins may have on
human gut bacteria and test the theorized protective qualities of the cyclodextrincholesterol complexes.
The human microbiome has become the focus of research for a variety of diseases
because of its connectivity to human health. Atherosclerosis is no exception; distinct
changes in the human gut microbiome have been noted in patients with atherosclerosis
(Jie et al. 2017). Analysis of these changes of bacteria found that inflammation increased
when certain strains of bacteria were decreased in vivo (Yoshida, Naofumi Emoto, Takuo
Yamashita 2018). Clostridium bolteae and Bacteroides vulgatus are anaerobic bacteria
found in the human gut microbiome (Maier et al. 2018). Each has their own unique
properties and benefits for overall health. B. vulgatus was studied specifically in mice
with induced atherosclerosis and was found to have anti-inflammatory effects (Yoshida,
Naofumi Emoto, Takuo Yamashita 2018). This is an important piece of information
because the genus, Bacteroides, was found to be less prevalent in the gut of mice that
were fed a high fat diet. On the other hand, C. bolteae is a member of Clostridium cluster
XIVa which was found to be increased in mice being fed a high fat diet (Nihei et al.
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2018). These changes can be seen in the figure above. Clostridium bacteria have been
found to both be proinflammatory and to help regulate inflammation depending on the
species (Barnes and Powrie 2011). A healthy balance of gut bacteria is key to a healthy
host. It is vitally important to be aware of how different treatments affect microbiome
health to ensure that they are as beneficial as possible and do not have unforeseen side
effects. Cyclodextrins could be damaging these bacterial membranes by removing
cholesterol from them, or through a different mechanism, but either way it is important to
see if these bacteria are being negatively affected by cyclodextrin treatment. The human
microbiome plays an important role in atherosclerosis so the health of these bacteria is
vital and should be considered when testing possible treatments.
Despite the promising data suggesting that cyclodextrins may help to regress
atherosclerotic plaques, the specific, direct effects of cyclodextrins on the gut bacteria B.
vulgatus and C. bolteae are not clear. In vivo studies are plagued by complex variables
that are difficult to control. Isolating individual bacteria for testing can negate these
variables. B. vulgatus was decreased in both human and mouse studies when under
atherosclerotic conditions, while C. bolteae was decreased when αCD was introduced
into the diet of the mice. This leads to the central questions being addressed in this
current proposal: what are the effects of cyclodextrins on these bacterial strains, and does
co-treatment with cholesterol change those effects? Cholesterol and cyclodextrins form
complexes with a dimer of cyclodextrins pulling a cholesterol molecule in and this
complexation may combine the potentially harmful chemicals into a harmless complex.
Based on the changes that occur in vivo the following hypotheses were developed:
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1. Bacteroides vulgatus will have decreased growth when grown in broth with
cholesterol. 2. Clostridium bolteae will have decreased growth when grown in broth with
cyclodextrins.
METHODS
Materials
Clostridium bolteae – ATCC
Bacteroides vulgatus – ATCC
αCD 98% (100g) – Fischer Scientific
HPβCD mw ~ 1540 (100g) – Fischer Scientific
Cholesterol 92.5% (25g) – Sigma Aldrich
Gifu Anaerobic Broth (500g) – Thomas Scientific
Falcon Tubes (12mL)
Single use sterile pipets (1mL, 5mL & 10mL)
Equipment
UV/VIS spectrophotometer
Shaking water bath incubator
Carbon Dioxide gas tank
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Methods
Bacteroides vulgatus was revived from frozen stock in gifu anaerobic broth
(GAM) in a shaking water incubator. Growth curves were determined using the same
procedure for each trial: two bacterial falcon tubes were made containing 10 mL of fresh
broth and 0.5 mL of bacteria containing broth. These tubes were made anaerobic by
filling them with carbon dioxide gas then immediately sealing them. 1 mL samples were
taken every hour, alternating between two tubes. Every time a tube was opened it was
filled with carbon dioxide again. The absorbance of these samples were immediately
measured at 560 nm using the UV/Vis spectrophotometer. The absorbance and time of
each sample were recorded to create the growth curve. Untreated samples were tested
every hour for 6 hours followed by two additional tests with two hour gap. This was
found to accurately capture the growth curve of B. vulgatus and was used for the
experimental trials as well. αCD, HPβCD, and cholesterol were all tested individually at
three different concentrations: 1mM, 10mM and 100mM. Three trials were run for each
treatment to limit random error. Combined trials were run for these four different
concentrations: 100mM αCD +100mM cholesterol, 100mM αCD +50mM cholesterol,
100mM HPβCD +100mM cholesterol, and 100mM HPβCD +50mM cholesterol. Each
combination was run with two trials each.
Clostridium bolteae was rehydrated from a freeze-dried stock in GAM broth in a shaking
water bath then frozen stocks were made the same way as previously stated. All methods
were the same for C. bolteae apart from the times that samples were taken. The
absorbances were recorded at these times: 0.5hr, 1hr, 2hr, 2.5hr, 3hr, 4hr, 5hr, 6hr.
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Growth curves were by measuring the slope of the log phase growth where the linear
upward slope was found. The slopes of each trial were compared to the slopes of the
control with a two-tailed T-test. The data is displayed as means +/- standard deviation
and P values of less than 0.05 will be used as the threshold for determining statistical
significance.
RESULTS
Bacteroides vulgatus and Clostridium bolteae have nine different growth curves
for the nine treatments. The standard growth curve follows a sigmoidal shape with a
linear growth period. The slope of the linear growth was found using a line of best fit.
The slopes were compared to a standard control slope. Figure 2 shows all three alpha
cyclodextrin treatments for Bacteroides vulgatus along with a control curve. The right
graph shows the curves after they have been cropped to only display the linear growth
period. Of the three alpha cyclodextrin treatments on Bacteroides vulgatus only 100 mM
was shown to significantly decrease growth.

Figure 2. The effects of alpha cyclodextrin on Bacteroides vulgatus growth. These two graphs display the
same set of data. The data displayed were from mean values with error bars showing 1 standard deviation.
The second graph has been cropped to only display the linear segment of growth. The line of best fit was
found for this segment then compared using a two-tailed T-test.
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Bacteroides vulgatus had decreased growth with two treatments and two other
treatments had increased growth. 1 mM and 10 mM cholesterol showed a significant
increase in growth rate. 100 mM concentrations of cholesterol and αCD were shown to
inhibit growth. Figure 3 depicts the growth curves for all four treatments along with a
standard growth curve.

Figure 3. These graphs are depicting all the results that were statistically significant for Bacteroides
vulgatus. T-test was run with alpha = 0.05 to compare the slopes of the log phase.

Clostridium bolteae had a statistically significant decrease in growth for eight of
the nine treatments. All HPβCD and all cholesterol along with 1 mM and 100 mM αCD
were shown to inhibit Clostridium bolteae growth. Theses eight treatment have a growth
curve that is displayed in figure 4.
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Figure 4. These graphs are depicting all the results that were statistically significant for Clostridium
bolteae. T-test was run with alpha = 0.05 to compare the slopes of the log phase growth. All the
concentrations shown were inhibiting growth.

Table 1 includes all the mean slope values with one standard deviation along with
their corresponding p values. The minimum significant p value is 0.05. There are twelve
statistically significant treatments between both of the bacteria tested.
Table 1. Results from Bacteroides vulgatus and Clostridium bolteae under varying conditions. Slopes from
the log phase of graphs for each trial were analyzed by a two- tailed t-test, p values are shown below. There
were varied levels of significance, values with p≤0.05 are marked with *, p≤0.01 is marked with **, and
p≤0.001***.

Bacteroides vulgatus
Treatment

Concentration

Control
Alpha Cyclodextrin

Beta Cyclodextrin

Slope ± 1SD

Clostridium bolteae

T.TEST p value

0.0034 ± 0.00036

Slope ± 1SD

T.TEST p value

0.0052 ± 0.0002

1mM

0.00353 ± 0.00029

0.6433

0.00403 ± 0.00058

0.02973*

10mM

0.00367 ± 0.000058

0.2746

0.0052 ± 0.00035

1

100mM

-0.000053 ± 0.000021

0.00007785***

-0.000087 ± 0.000058

0.000001363***

1mM

0.0034 ± 0.0001

1

0.00423 ± 0.0004

0.0206*

10mM

0.00357 ± 0.000058

0.4734

0.00413 ± 0.00042

0.01613*

100mM

0.00303 ± 0.000058

0.157

0.00357 ± 0.00071

0.01849*

1mM

0.00603 ± 0.00015

0.000311***

0.00463 ± 0.00012

0.01316*

Cholesterol
10mM

0.0048 ± 0.00066

0.03166*

0.00353 ± 0.00029

0.001194**

100mM

-0.00022 ± 0.000144

0.00008642***

-0.00005 ± 0.00001

0.000001407***
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DISCUSSION
Bacteroides vulgatus was treated with nine different trials. Of those nine trials,
four were statistically significant and this can be seen in table 1. Although five of the nine
trials showed no significant change in growth, these are still important trials. 2hydroxypropyl-β-cyclodextrin is specifically designed to be less toxic, the added
hydroxypropyl groups decrease the affinity for cholesterol which has been shown to
lower the toxicity (Szente et al. 2018). The data for Bacteroides vulgatus is consistent
with this purpose, even at 100 mM concentration the growth of this bacteria was not
significantly inhibited. α-cyclodextrin is unsubstituted but this does not mean there are no
toxic effects. On the contrary the toxic effects can be seen in the trial when Bacteroides
vulgatus was treated with 100 mM α-cyclodextrin and it was significantly inhibited. This
inhibition is not present at lower concentrations. This is consistent with the previous
study that α-cyclodextrin is slightly more toxic than 2-hydroxypropyl-β-cyclodextrin but
both are still being studied as treatments for atherosclerosis (Szente et al. 2018). The
hypothesis for Bacteroides vulgatus was that it would be inhibited when grown in broths
with cholesterol. This was based on study by Jie et al. on patients with atherosclerosis
where their gut microbiome was analyzed for consistent changes occurring in most
atherosclerotic patients. The Bacteroides genus was decreased in general, and it was
suspected that these bacteria grow poorly under high fat conditions that usually
associated with atherosclerosis. This was supported by the study done by Nihei et al. on
mice. Cholesterol was tested because of the limited ability to replicate a high fat diet in
vitro. This hypothesis is supported at 100 mM cholesterol concentrations where
Bacteroides vulgatus was significantly inhibited. Surprisingly, 1 mM and 10 mM
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concentrations of cholesterol significantly increased the growth of Bacteroides vulgatus.
There was more increased growth in the 1 mM than the 10 mM then at 100 mM the
growth becomes inhibited. The mechanism for this increased growth in unknown. The
data presented for the lower concentrations of cholesterol contradict the predicted trend.
This may be to due to the fact that the studies were using high fat diets while this study
looked at cholesterol alone (Jie et al. 2017; Nihei et al. 2018). There is more research to
be done to see where the concentrations of cholesterol transitions from beneficial to
harmful. There is also a need for this study to be replicated to see if similar results are
being found. This is only one species in the Bacteroides genus and it would be beneficial
to learn if the entire genus reacts similarly to these conditions. It is difficult to draw large
conclusions based off a study on a specific bacteria when the gut microbiome is a diverse
population. The diversity of the microbiome is key to its function and a possible
unwanted side effect of cyclodextrins could be the destruction of that diversity.
Clostridium bolteae was treated with the same nine trials as Bacteroides vulgatus.
This bacteria was more susceptible to inhibition; it was significantly inhibited by eight of
the nine trials. Interestingly, the only trial that did not show any significant changes in
growth was 10 mM α-cyclodextrin. All other data was consistent with previous studies.
Similar to Bacteroides vulgatus, 100 mM concentrations of cholesterol and αcyclodextrin are inhibiting growth significantly. The slopes are nearly zero for these two
trials as it is seen in table 1. The lower concentrations of α-cyclodextrin and cholesterol,
with the exception of 10 mM α-cyclodextrin, make intuitive sense. The lower the
concentration, the lower the significance in growth inhibition. 2-hydroxypropyl-βcyclodextrin is expected to be less toxic than α-cyclodextrin. In 1 mM concentrations the
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two significance values are very similar and 10 mM concentrations are complicated.
When comparing the 100 mM concentration the expected result can be clearly seen. 100
mM α-cyclodextrin has a slope of nearly zero while 100 mM 2-hydroxypropyl-βcyclodextrin still shows growth. This is consistent with the idea presented earlier that 2hydroxypropyl-β-cyclodextrin is less toxic than α-cyclodextrin (Szente et al. 2018). The
hypothesis for Clostridium bolteae was that there would be inhibited growth when grown
in both with cyclodextrins. This is supported by results from a study on mice that were
treated with cyclodextrins, and they had decreased Clostridium populations (Nihei et al.
2018). In general, this is supported with the data from this study, except for 10 mM αcyclodextrin. It is key to note that Bacteroides vulgatus was unaffected by 2hydroxypropyl-β-cyclodextrin but Clostridium bolteae had significant growth inhibition
at all concentrations. This supports that hypothesis that Clostridium bolteae is specifically
inhibited by cyclodextrins even the one deemed safer than the others 2-hydroxypropyl-βcyclodextrin. Clostridium bolteae also showed significant growth inhibition for
cholesterol at all concentrations. In Jie’s study on atherosclerotic patients the Clostridium
genus was increased in these patients, unlike the Bacteroides genus. There is not research
supporting the decreased growth of Clostridium bolteae in cholesterol. Bacteroides
vulgatus is not entirely representative the Bacteroides genus but the Clostridium genus is
even more varied (Barnes and Powrie 2011). There is a need for further research on other
members of the Clostridium genus to explain the increase of the population under
atherosclerotic conditions. There is a possibility that Clostridium bolteae decreases but
other species thrive. This points to the importance of expanding the study to include a
large variety of species of gut bacteria.
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CONCLUSION
The results from these two bacteria show that cyclodextrins can inhibit gut
bacteria although further research should be done to see if this inhibition will be
universally detrimental to the gut microbiome. The results indicate that there is some
dose dependence on the inhibition. The health of gut microbiome composition should be
monitored in future clinical research. Further research is needed to fully understand the
general impact that cyclodextrins would have on the gut microbiome. This study was
limited by the small number of bacteria tested along with limited concentration range.
The maintenance of an anerobic environment was difficult to control and while it was
every attempt was made to control the environment, oxygen contamination could
contribute to the results. Overall, this research supports cyclodextrins having adverse side
effects on gut bacteria while raising new questions for future work.
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